Literature DB >> 18353729

Radiological treatment of symptomatic uterine fibroids.

M J Bratby1, A-M Belli.   

Abstract

Uterine artery embolization (UAE) is a relatively new alternative treatment for symptomatic fibroids. Recent Level 1 evidence from two major randomized controlled trials has established UAE as a safe and effective alternative to hysterectomy. Technical aspects, choice of embolic agent, safety, contra-indications and complications of the procedure will be reviewed. The available data on the effects on ovarian function, fertility and pregnancy outcomes following UAE will be presented.

Entities:  

Mesh：

Year:  2008        PMID： 18353729     DOI： 10.1016/j.bpobgyn.2008.01.013

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN： 1521-6934            Impact factor:   5.237


  5 in total

Review 1.  GnRH agonists: do they have a place in the modern management of fibroid disease?

Authors:  Vikram Sinai Talaulikar; Anna-Maria Belli; Isaac Manyonda
Journal:  J Obstet Gynaecol India       Date:  2012-09-27

2.  [Non-invasive thermoablation of symptomatic uterine fibroids with magnetic resonance-guided high-energy ultrasound].

Authors:  T Eckey; A Neumann; M K Bohlmann; J Barkhausen; P Hunold
Journal:  Radiologe       Date:  2011-07       Impact factor: 0.635

3.  Pregnancy after complex myomectomy: neither age of patient nor size, number or location of fibroids should be a barrier.

Authors:  Vikram Sinai Talaulikar; Sahana Gupta; Isaac Manyonda
Journal:  JRSM Short Rep       Date:  2012-03-26

4.  Uterine fibroid embolisation for symptomatic uterine fibroids: a survey of clinical practice in Europe.

Authors:  Marianne J Voogt; Mark J Arntz; Paul N M Lohle; Willem P Th M Mali; Leo E H Lampmann
Journal:  Cardiovasc Intervent Radiol       Date:  2010-09-21       Impact factor: 2.740

Review 5.  Uterine artery embolization for treatment of symptomatic fibroids: a review of the evidence.

Authors:  Kavous Firouznia; Hossein Ghanaati; Amir Hossein Jalali; Madjid Shakiba
Journal:  Iran Red Crescent Med J       Date:  2013-12-05       Impact factor: 0.611
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.